Quiz 2 ClinPharm LEC

1234567891011121314
Across
  1. 5. An abnormal permanent enlargement of the airspaces distal to the terminal bronchioles accompanied by destruction of their walls without obvious "fibrosis”.
  2. 9. It is a long-acting B2 agonist that has a slower onset of action
  3. 10. It is generally defined as an arterial blood carbon dioxide level over 45 mmHg
  4. 12. It represents the single most important intervention in preventing the development, as well as progression, of COPD.
  5. 13. An oral PDE4 inhibitor that is recommended for patients with recurrent exacerbations despite treatment with triple inhalation therapy
  6. 14. This drug can relieve dyspnea for patients with end-stage COPD.
Down
  1. 1. It is present early in the course of the COPD and is associated with an increased number and size of mucus-producing cells
  2. 2. This is considered an alternative to commonly used inhaled therapies for bronchodilation and improving symptoms.
  3. 3. It is the most frequently used short-acting B2-agonist
  4. 4. It is the most prescribed short-acting anticholinergic agent for COPD in the United States.
  5. 6. It is typically the most troublesome complaint for patients with COPD
  6. 7. This the preferred route of administration for short-acting, selective B2-agonists
  7. 8. This is the initial recommended therapy for COPD patients who experience occasional symptoms
  8. 11. It is a right-sided heart failure secondary to pulmonary hypertension
  9. 12. This test is useful to confirm the presence of airflow limitation and to determine the severity of obstruction.